{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:49:17Z","timestamp":1767340157918},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advances in Dermatology"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.yadr.2007.07.003","type":"journal-article","created":{"date-parts":[[2007,11,21]],"date-time":"2007-11-21T15:33:32Z","timestamp":1195659212000},"page":"155-163","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["The Efficacy and Safety of Amoxicillin, Trimethoprim-Sulfamethoxazole, and Spironolactone for Treatment-Resistant Acne Vulgaris"],"prefix":"10.1016","volume":"23","author":[{"given":"Cheryl Bansal","family":"Turowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William D.","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.yadr.2007.07.003_bib1","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1056\/NEJMcp033487","article-title":"Acne","volume":"352","author":"James","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.yadr.2007.07.003_bib2","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2133.1971.tb14233.x","article-title":"A comparison of trimethoprim-sulphamethoxazole with oxytetracycline in acne vulgaris","volume":"84","author":"Cotterill","year":"1971","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.yadr.2007.07.003_bib3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000252042","article-title":"Trimethoprim-sulphamethoxazole in acne vulgaris: a double-blind study","volume":"145","author":"Hersle","year":"1972","journal-title":"Dermatologica"},{"issue":"2","key":"10.1016\/j.yadr.2007.07.003_bib4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1742-1241.1972.tb04388.x","article-title":"Trimethoprim-sulphamethoxazole versus placebo in acne vulgaris","volume":"26","author":"Macdonald","year":"1972","journal-title":"Br J Clin Pract"},{"issue":"2","key":"10.1016\/j.yadr.2007.07.003_bib5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-2133.1982.tb00342.x","article-title":"Oral trimethoprim versus oxytetracycline in the treatment of inflammatory acne vulgaris","volume":"107","author":"Gibson","year":"1982","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.yadr.2007.07.003_bib6","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1046\/j.1365-2133.1999.03132.x","article-title":"Oral trimethoprim: a relatively safe and successful third-line treatment for acne vulgaris","volume":"141","author":"Cunliffe","year":"1999","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.yadr.2007.07.003_bib7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2165\/00128071-200304050-00002","article-title":"Antibacterial therapy for acne: a guide to selection and use of systemic agents","volume":"4","author":"Tan","year":"2003","journal-title":"Am J\u00a0Clin Dermatol"},{"key":"10.1016\/j.yadr.2007.07.003_bib8","doi-asserted-by":"crossref","first-page":"730","DOI":"10.4065\/74.7.730","article-title":"Trimethoprim-sulfamethoxazole","volume":"74","author":"Smilack","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.yadr.2007.07.003_bib9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1542\/pir.25-11-375","article-title":"Trimethoprim-sulfamethoxazole: clinical update","volume":"25","author":"Libecco","year":"2004","journal-title":"Pediatrics in Review"},{"key":"10.1016\/j.yadr.2007.07.003_bib10","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/S0025-6196(12)62478-1","article-title":"Trimethoprim-sulfamethoxazole","volume":"66","author":"Cockerill","year":"1991","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.1016\/j.yadr.2007.07.003_bib11","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S0025-7125(16)30805-7","article-title":"Trimethoprim-sulfamethoxazole and other sulfonamides","volume":"71","author":"Foltzer","year":"1987","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.yadr.2007.07.003_bib12","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/clinids\/4.2.429","article-title":"Adverse reactions to trimethoprim-sulfamethoxazole","volume":"4","author":"Lawson","year":"1982","journal-title":"Rev Infect Dis"},{"issue":"4","key":"10.1016\/j.yadr.2007.07.003_bib13","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/j.1875-9114.1995.tb04378.x","article-title":"A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim, and cephalexin for uncommon serious drug toxicity","volume":"15","author":"Jick","year":"1995","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.yadr.2007.07.003_bib14","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1046\/j.1365-2125.1997.00590.x","article-title":"Hospitalization for serious blood and skin disorders following co-trimoxazole","volume":"43","author":"Myers","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.yadr.2007.07.003_bib15","doi-asserted-by":"crossref","first-page":"420","DOI":"10.7326\/0003-4819-91-3-420","article-title":"Trimethoprim-sulfamethoxazole in the United States","volume":"91","author":"Wormser","year":"1979","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.yadr.2007.07.003_bib16","first-page":"893","article-title":"Drug therapy reviews: trimethoprim-sulfamethoxazole","volume":"36","author":"Gleckman","year":"1979","journal-title":"Am J Hosp Pharm"},{"key":"10.1016\/j.yadr.2007.07.003_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajh.2830230102","article-title":"Studies of the effects of trimethoprim and sulfamethoxazole on human granulopoeisis","volume":"23","author":"Bjornson","year":"1986","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.yadr.2007.07.003_bib18","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0890-6238(01)00178-2","article-title":"The teratogenic risk of trimethoprim-sulfonamides: a population based case-control study","volume":"15","author":"Czeizel","year":"2001","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.yadr.2007.07.003_bib19","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1177\/106002809302700922","article-title":"Trimethoprim-sulfamethoxazole-induced rash, fever, abnormal liver function tests, leukopenia, and thrombocytopenia","volume":"27","author":"Malnick","year":"1993","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.yadr.2007.07.003_bib20","first-page":"429","article-title":"Severe thrombocytopenia-hemorrhage due to trimethoprim-sulfamethoxazole: a case report","volume":"4","author":"Ahmad","year":"1982","journal-title":"Rev Infect Dis"},{"issue":"2","key":"10.1016\/j.yadr.2007.07.003_bib21","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/clinids\/4.2.426","article-title":"Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients","volume":"4","author":"Jick","year":"1982","journal-title":"Rev Infect Dis"},{"issue":"2","key":"10.1016\/j.yadr.2007.07.003_bib22","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/j.jinf.2005.05.008","article-title":"Trimethoprim-sulfamethoxazole induced rash and fatal hematologic disorders","volume":"52","author":"Kocak","year":"2006","journal-title":"J Infect"},{"key":"10.1016\/j.yadr.2007.07.003_bib23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1345\/aph.1A188","article-title":"Severe thrombocytopenia possibly associated with TMP-SMX therapy","volume":"36","author":"Yamreudeewong","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.yadr.2007.07.003_bib24","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/archinte.1989.00390050040008","article-title":"Anti-infective drug use in relation to the risk of agranulocytosis and aplastic anemia","volume":"149","author":"[Author unknown]","year":"1989","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.yadr.2007.07.003_bib25","doi-asserted-by":"crossref","first-page":"291","DOI":"10.7326\/0003-4819-119-4-199308150-00007","article-title":"Trimethoprim-sulfamethoxazole induces reversible hyperkalemia","volume":"199","author":"Greenberg","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.yadr.2007.07.003_bib26","doi-asserted-by":"crossref","first-page":"316","DOI":"10.7326\/0003-4819-124-3-199602010-00006","article-title":"Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole","volume":"124","author":"Alappan","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.yadr.2007.07.003_bib27","first-page":"187","article-title":"Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose","volume":"46","author":"Perazella","year":"1996","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.yadr.2007.07.003_bib28","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0272-6386(97)90473-X","article-title":"Hyperkalemia and trimethoprim-sulfamethoxazole","volume":"29","author":"Ellison","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.yadr.2007.07.003_bib29","doi-asserted-by":"crossref","first-page":"296","DOI":"10.7326\/0003-4819-119-4-199308150-00008","article-title":"Renal mechanism of trimethoprim-induced hyperkalemia","volume":"119","author":"Velazquez","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.yadr.2007.07.003_bib30","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1128\/AAC.41.11.2466","article-title":"Effects of moderate-dose versus high-dose trimethoprim on serum creatinine and creatinine clearance and adverse reactions","volume":"41","author":"Naderer","year":"1997","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Advances in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882088007000041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882088007000041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T12:30:25Z","timestamp":1708345825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0882088007000041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":30,"alternative-id":["S0882088007000041"],"URL":"https:\/\/doi.org\/10.1016\/j.yadr.2007.07.003","relation":{},"ISSN":["0882-0880"],"issn-type":[{"value":"0882-0880","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}